MedTrace Logo

Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy

NCT00200850 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2019-06-12

Study results available
· View outcomes & findings →

Summary

This study will investigate sublingual immunotherapy (SLIT), a treatment involving antigens placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing substances. Specifically, this study will determine the effectiveness of SLIT at two different dosing regimens for patients with intermittent mild asthma caused by dust mites.

Conditions

Interventions

BIOLOGICAL

House Dust Mite SLIT

low dose SLIT 143 Allergen Units(AU)/ml daily

BIOLOGICAL

High dose SLIT

House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily

BIOLOGICAL

Placebo SLIT

Placebo SLIT daily

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Robert K. Bush, MD · University of Wisconsin Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00200850 on ClinicalTrials.gov